Browse related articlesNew medical product development centre opens in Jordan
Jordan: Thursday, October 30 - 2008 at 08:59
The new Philadelphia Biological and Medical Product Development Centre is to open today in Amman, Jordan. The Centre will be the only healthcare product development hub worldwide that provides preclinical evaluation, full-service clinical research, core lab facilities, as well as cell engineering and culturing, according to a press release. Peggy Farley, the Centre's Chairperson, said the centre will place the Middle East firmly on the map as a global medical technology leader. Farley is also co-founder of the Ascent Medical Technology Funds, including Fund II which is the financial instrument providing the funding for the project. Recently, the Centre successfully carried out a Bioheart Inc sponsored study to support the treatment of potentially life-threatening, heart-related aliments that saw positive results of a pre-clinical study of the Adipose-Derived Stem Cells (ADSCs) therapy study for heart patients.
See Also
Also consider reading:
- » Foreign trips for medical travel often rejected
- » Kuwait clinic offers new arthritis procedures
- » Specialist children's hospital plan for Saudi
- » Rotavirus vaccine successful
- » New hospital opens in Dubai Healthcare City
- » UAE onboard UN body on tropical disease
- » New medical residency medical centre to open in Dubai
- » Health services 'failing' underprivileged
- » Qatar shows highest diabetes rate
- » WHO to assist Qatar
Facebook
LinkedIn
Digg
Jeff Florian, Senior ReporterThursday, October 30 - 2008 at 08:59 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Disclaimer:
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
Web Feeds